View
2
Download
0
Category
Preview:
Citation preview
Canadian Society of Internal Medicine Annual Meeting 2016
Montreal, QC
CLINICAL PREDICTORS AND BIOMARKERS IN PREECLAMPSIA: WHAT
SHOULD WE TELL OUR PATIENTS?
Dr Evelyne Rey, Obstetric Medicine Division, CHU Sainte-Justine, University of Montreal
Montreal
1
Canadian Society of Internal Medicine Annual Meeting 2016
Montreal, QC
Someofthedrugs,devices,ortreatmentmodalitiesmentionedinthispresentationare:aspirin
No Conflict Disclosures
E. Rey. CLINICAL PREDICTORS AND BIOMARKERS IN PREECLAMPSIA. 2016-10-29 2
Canadian Society of Internal Medicine Annual Meeting 2016
Montreal, QC
The following presentation represents the views of the speakerat the time of the presentation. This information is meant for educational purposes, and should not replace other sources
of information or your medical judgment.
E. Rey. CLINICAL PREDICTORS AND BIOMARKERS IN PREECLAMPSIA. 2016-10-293
CSIM2016
OBJECTIVES
• Identifyspecificelementsfrompastmedicalhistory,physicalexaminationandobstetrichistorythatcanhelppredictpreeclampsia
• Selectpatientsthatcanbenefitfromimagingtechniquestohelppredictpreeclampsia
• Recognizetheclinicalutilityofexistingorpromisingbiomarkersforpredictionofpreeclampsia(PE)
4
CSIM2016
PLAN
• Physiology
• Predictors– Clinicalriskfactors
– Biomarkers
– Doppler
– Cell-freefetalDNA
– Podocyturia,Microalbuminuria
• Cases
5
CSIM2016
PartialmaternaltoleranceofallogenictrophoblastStage1
Stage2
ModifiedfromRedmanCW2005
6
CSIM2016 Adapted from Redman 20057
CSIM2016
PartialmaternaltoleranceofallogenictrophoblastStage1
Stage2
Stage3
ModifiedfromRedmanCW2005
Sub-clinicalinflammation,genetics,behavioralfactors
8
CSIM2016
PartialmaternaltoleranceofallogenictrophoblastStage1
Stage2
Stage3
Placentalmarkers
ModifiedfromRedmanCW2005
Sub-clinicalinflammation,genetics,Behavioralfactors
• ↓PP13• ↓PAPP-A• ↓ADAM12• ↓Metastin
• ↓β-hCG
• ↑Activin-A
• ↑Inhibin-A
9
CSIM2016
PartialmaternaltoleranceofallogenictrophoblastStage1
Stage2
Stage3
Vascularmarkers
ModifiedfromRedmanCW2005
AngiogenicF.
↓VEGF↓PlGF
AntiAngiogenicF.↑sFlt-1 ↑sEndoglin
↑sFlt-1/PlGF
10
CSIM2016
PartialmaternaltoleranceofallogenictrophoblastStage1
Stage2
Stage3
Imaging
ModifiedfromRedmanCW2005
11
CSIM2016
PartialmaternaltoleranceofallogenictrophoblastStage1
Stage2
Stage3
ModifiedfromRedmanCW2005
PredictionProphylaxisPreventoccurrencePreventseverity
EarlydiagnosisPrognosisClosematernalandfetalfollow-up
Severityprediction,Transfer,Delivery
12
CSIM2016
CLINICALRISKFACTORS
• Familyhistory
• Personalmedicalhistory
• Demographiccharacteristics
• Pregnancy-relatedfactors
13
CSIM2016
MageeLASOGC2008
14
CSIM2016 15
BartschE.BMJ2016
CSIM2016
CLINICALRISKFACTORS
PredictorModelsMetaanalysisAL-RubaieZTAetalBJOG2016
ParityPreviousPEEthnicitycHTConceptionmethodMeanBP
EPESensitivity70%Specificity70%
16
Poonetal.
17
BLOODPRESSURE
CSIM2016
UADOPPLERVELOCIMETRY1stT• Sensitivity48%,specificity92%• Notalone• NotdoneroutinelyinCanada
18
When?AnytimeifIUGR19-20w• Ifabnormalbiomarkers:usefulness?• IfriskofIUGR
LausmanA.JOGC2013
CSIM2016
BIOMARKERS
• Availability
• Aneuploidyscreening
– 1TPAPP-A
– 2T-hCG
–alphaFP–Estriol–Inhibin-A
19
CSIM2016
BIOMARKERS
1stT/earlysecondtrimester
– PAPP-A– Inhibin-A–PlGF
20
CSIM2016
Nicolaides2008
21
CSIM2016 22
EPE• Parity• PreviousPE• Ethnicity• cHT• Conception• MeanBP
LPE• +• FamilyHPE• Age• BMI
CSIM2016
OlivieraNetal.UltrasoundObstetGynecol2014
23
CSIM2016 24
CSIM2016
EFFICACYOFTHEMODELS?
• NoRCT
• ASPRE
• CohortscomparisonParksetal2015
25
CSIM2016
ParkFetal.UltrasundObstetGynecol2015;46:419
26
CSIM2016
Cell-freeFETALDNA• Increaseswithmarkersofplacentasize• Markerfortrophoblasticcelldeath• YuH2013:Increasesat11-14winEPE:sensitivity90%specificity85%
27
NEXTMARKER?
LevineRJAJOG2004
CSIM2016
Medicaldictionnonary2011
28
CSIM2016
MollerCCetal.JAmSocNephrol2009
29
SCMI2016 30
CSIM2016
Craicietal.Hypertension2013:1289-96
Lateentryinthestudy
PODOCYTURIA
31
SCMI2016
MICROALBUMINURIA< 20wks
– Lowrisk:no
– cHtorpreviousPreeclampsia
• higherlevel• Laura-Gonzalez2003:20mg/l
–Sensitivity79%etspecificity63%
–PPV46%NPV88%
32
CotéAMCurrentHypertensionreviews2010
CSIM2016
MICROALBUMINURIAINDB
• StrongriskfactorforPE• JensenDMDiabCare2010:846womenT1DB
–NoMicroA:12%PEvs
–MicroA:40%PE
–MicroA:ORa4,nulliparityORa3
•CastiglioniMTPregnancyHyper2014– cHTOR17(3-91),MicroAOR3.8(1.2-11.6),1TGHcOR2.8(1.1-7)
33
CSIM2016 34
CSIM2016
Case1
• Kimberly,29y,G1P0,
• Essentialchronichypertension
• Blackrace
• BMI36
• 154/104at12w
35
Riskofpreeclampsia?.5-10%.10-20%.20-30%.>30%
CSIM2016 36
BartschE.BMJ2016
BramhamK.BMJ2014
CSIM2016 38
CSIM2016 39
Abnormalif< 0.4MoM
CSIM2016
Case2
• Sandra,37y,G1,
• Type2DBx10y.Notsmoking
• Whiterace
• BMI44
• BP114/76at15w
40
Riskofpreeclampsia?
.5-10%
.10-20%
.20-30%
.>30%
SCMI2016
OTHERINFORMATION?
GH
41
Sandra=7.9%
Microalbuminuria
Sandra=none
CSIM2016
MICROALBUMINURIAINDB
• StrongriskfactorforPE• JensenDMDiabCare2010:846womenT1DB
–NoMicroA:12%PEvs
–MicroA:40%PE
–MicroA:ORa4,nulliparityORa3
• CastiglioniMTPregnancyHyper2014
– cHTOR17(3-91),MicroAOR3.8(1.2-11.6),1TGHcOR2.8(1.1-7)
42
CSIM2016 43
Abnormalif< 0.4MoM
CSIM2016
Case3
• Mandy,35y,G2P1
• PreviousEPE25w+IUGR.CS27w.
• Blackrace,BMI25
• BP130/80
44
Riskofpreeclampsia?
.10-20%
.20-30%
.30-40%
.>40%
CSIM2016
OTHERINFORMATION?
• Placenta• Recurrence• Vascularmalperfusionlesionsassociatedwithrecurrence
WeinerE.PrenatalDiagnosis2015
45
CSIM2016 46
Abnormalif< 0.4MoM
SCMI2016
Preeclampsiarisk?
Dany Suzy
Age 22 29
BMI 30.2 24.8
Race White Black
BP12sem 120/50 120/80
PAPP-A 0.34 1.72
47
HypothyroïdismNonsmokingG1NoFHofPrE
ClinicalF. 4.8% 6.9%
+MAPANDPAPP-A
2.1% 7.3%
SCMI2016
CONCLUSIONS
• HIGHRISKdefinedbyCLINICALFACTORS:REMAINMAJORTOOL
• Impactofbiomarkersonthisgroupofwomen?
• Biomarkersinmoderateriskwomenmoreuseful?
48
CSIM2016 49
HAVEALOOK!GEMOQ.CA
JOINUSATtheNASOM/GEMOQmeeting
CSIM2016 50
WithoutpreviousEPE
SCMI2016 51
BartschE.BMJ2016
Recommended